Abstract
Resolution of inflammation, an actively coordinated program, is essential to maintain host health. It involves effective removal of inflammatory stimuli and the spatio-temporal control of leukocyte trafficking as well as chemical mediator generation. During the active resolution process, new classes of small, local acting endogenous autacoids, namely the lipoxins, D and E series resolvins, (neuro)protectins, and maresins have been identified. These specialized proresolving lipid mediators (SPM) prevent excessive inflammation and promote removal of microbes and apoptotic cells, thereby expediting resolution and return to tissue homeostasis. As part of their molecular mechanism, SPM exert their potent actions via activating specific pro-resolving G-protein coupled receptors. Together these SPM and their receptors provide new concepts and opportunities for therapeutics, namely promoting active resolution as opposed to the conventionally used enzyme inhibitors and receptor antagonists. This approach may offer new targets suitable for drug design for treating inflammation related diseases, for the new terrain of resolution pharmacology.
Keywords: G-protein coupled receptor, inflammatory exudates, leukocytes, mediator lipidomics, omega-3 fatty acids, resolvins, trafficking, specialized proresolving lipid mediators, antagonists, TNF, prostaglandins, arthritis, lipoxins, potent chemoattractants, Protectins
Current Topics in Medicinal Chemistry
Title: Novel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors
Volume: 11 Issue: 6
Author(s): Charles N. Serhan, Sriram Krishnamoorthy, Antonio Recchiuti and Nan Chiang
Affiliation:
Keywords: G-protein coupled receptor, inflammatory exudates, leukocytes, mediator lipidomics, omega-3 fatty acids, resolvins, trafficking, specialized proresolving lipid mediators, antagonists, TNF, prostaglandins, arthritis, lipoxins, potent chemoattractants, Protectins
Abstract: Resolution of inflammation, an actively coordinated program, is essential to maintain host health. It involves effective removal of inflammatory stimuli and the spatio-temporal control of leukocyte trafficking as well as chemical mediator generation. During the active resolution process, new classes of small, local acting endogenous autacoids, namely the lipoxins, D and E series resolvins, (neuro)protectins, and maresins have been identified. These specialized proresolving lipid mediators (SPM) prevent excessive inflammation and promote removal of microbes and apoptotic cells, thereby expediting resolution and return to tissue homeostasis. As part of their molecular mechanism, SPM exert their potent actions via activating specific pro-resolving G-protein coupled receptors. Together these SPM and their receptors provide new concepts and opportunities for therapeutics, namely promoting active resolution as opposed to the conventionally used enzyme inhibitors and receptor antagonists. This approach may offer new targets suitable for drug design for treating inflammation related diseases, for the new terrain of resolution pharmacology.
Export Options
About this article
Cite this article as:
N. Serhan Charles, Krishnamoorthy Sriram, Recchiuti Antonio and Chiang Nan, Novel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors, Current Topics in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/1568026611109060629
DOI https://dx.doi.org/10.2174/1568026611109060629 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High-Density Lipoprotein-Raising Strategies: Update 2010
Current Pharmaceutical Design The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Plant-Derived Biomolecules and Drug Delivery Systems in the Treatment of Liver and Kidney Diseases
Current Pharmaceutical Design An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy <i>Nigella sativa</i>, as Preventive Strategy in COVID-19
Current Traditional Medicine Neuronal Regulators and Vascular Dysfunction in Raynauds Phenomenon and Systemic Sclerosis
Current Vascular Pharmacology Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Use of Naturally Occurring Peptides for Neuropathic Spinal Cord Injury Pain
Current Protein & Peptide Science Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine A Review of Research Progress on <i>Agathis dammara</i> and its Application Prospects for Cardiovascular Diseases and Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry Recent Advances on Neural Tube Defects with Special Reference to Valproic Acid
Endocrine, Metabolic & Immune Disorders - Drug Targets Sida cordifolia, a Traditional Herb in Modern Perspective – A Review
Current Traditional Medicine What have Genetically Engineered Mice Taught Us About Ischemic Injury?
Current Molecular Medicine Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
CNS & Neurological Disorders - Drug Targets Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets